← Browse by Condition
Medical Condition

antiphospholipid syndrome

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for antiphospholipid syndrome sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — antiphospholipid syndrome Clinical Trials

How many clinical trials are currently recruiting for antiphospholipid syndrome?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for antiphospholipid syndrome, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for antiphospholipid syndrome?
antiphospholipid syndrome research spans Phase 1 (1 trial), Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a antiphospholipid syndrome clinical trial?
Eligibility criteria for antiphospholipid syndrome trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
1
Top Sponsors
China Immunotech (Beijing) Biotechnology Co., Ltd. 1 trial
Stéphane Zuily 1 trial
Peking University People's Hospital 1 trial
University Hospital, Strasbourg, France 1 trial

Recruiting Clinical Trials

NCT07236801 Phase 1
Recruiting
Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases
Enrollment
18 pts
Location
China
Sponsor
China Immunotech (Beijing) Bio...
View Trial →
NCT04262492
Recruiting
International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants
Enrollment
500 pts
Location
France
Sponsor
Stéphane Zuily
View Trial →
NCT06794008 Phase 2
Recruiting
BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
Enrollment
50 pts
Location
China
Sponsor
Peking University People's Hos...
View Trial →
NCT07251179
Recruiting
Characterization of Autoreactive b Lymphocytes in Autoimmune Diseases and Immune Deficiencies
Enrollment
200 pts
Location
France
Sponsor
University Hospital, Strasbour...
View Trial →

Related Conditions

inflammatory myopathy (2) systemic lupus erythematosus (2) anca associated vasculitis (2) systemic lupus erythematosus sle (1) systemic sclerosis (1) sjogren s syndrome ss (1) anti neutrophil cytoplasmic antibody associated vasculitis (1) thrombosis (1) anticoagulants causing adverse effects in therapeutic use (1) systemic sclerosis ssc (1) igg4 related diseases (1) acquired thrombotic thrombocytopenic purpura (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology